STOCK TITAN

Alimera Sciences - ALIM STOCK NEWS

Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.

Overview

Alimera Sciences (Nasdaq: ALIM) is a specialized pharmaceutical company devoted to the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Focused on innovative treatments for retinal diseases, Alimera addresses significant clinical gaps in treating conditions that affect millions of individuals, particularly in aging populations.

Core Business and Product Technology

The company centers its efforts on diseases impacting the back of the eye, leveraging advanced sustained release technologies such as its CONTINUOUS MICRODOSING™ platform. With products that deliver sub-microgram levels of fluocinolone acetonide over extended durations, Alimera’s treatments help reduce injection frequency and aim to maintain patient vision longer. This approach not only reflects the firm’s commitment to precision drug delivery but also highlights its role in solving a critical unmet need within the ophthalmology sector.

Market Position and Specialization

Operating in a highly specialized niche, Alimera Sciences is well-regarded among retina specialists due to its focused portfolio designed to treat both early- and late-stage retinal diseases. The company serves a global market with a dual focus: in the United States, it addresses conditions such as diabetic macular edema and uveitis with its various approved indications, while in Europe, through its London-based subsidiary, it caters to patients with limited treatment options. This clear segmentation underscores Alimera's expertise in managing complex retinal conditions.

Clinical Research and Development

Alimera's robust research and development efforts are integral to its business model. The company pursues evidence-based strategies through clinical trials and scientific programs that aim to validate the efficacy and safety of its ophthalmic products. By engaging with networks such as the DRCR Retina Network and participating in prominent conferences, Alimera reinforces its commitment to advancing clinical knowledge in ophthalmology and to addressing complications like radiation retinopathy.

Global Operations and Strategic Impact

With international operations that ensure outreach to diverse markets, Alimera Sciences integrates clinical insights and patient needs into a comprehensive global strategy. Its operational model supports ranging therapeutic indications and demonstrates adaptability across regulatory landscapes, reinforcing its steadiness in a competitive industry. The company's expertise in sustained drug delivery not only bolsters its clinical credibility but also positions it as an essential resource for both physicians and patients seeking improved retinal health outcomes.

Commitment to Excellence

Alimera Sciences exemplifies dedication to clinical excellence and innovation. The company’s focus on retinal health through cutting-edge technology, combined with a patient-centric approach, underpins its reputation in the pharmaceutical industry. Whether targeting non-infectious uveitis or conditions secondary to diabetic complications, Alimera’s balanced approach between clinical research and market application demonstrates its enduring commitment to delivering advanced ophthalmic therapies.

Rhea-AI Summary
Alimera Sciences, Inc. (ALIM) announces that the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending that patients with a natural lens being treated for chronic diabetic macular edema (DME) have access to ILUVIEN, a sustained-release treatment lasting up to 36 months. This recommendation could potentially benefit up to 75% of the overall DME population in the United Kingdom. NHS England and NHS Wales are expected to provide funding for this guidance shortly after publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none
-
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) has completed enrollment for the Synchronicity Study, evaluating the safety and efficacy of YUTIQ in the treatment of chronic non-infectious uveitis and related intraocular inflammation. The Phase 4 open-label study aims to provide retina specialists with a broader sense of the utility of fluocinolone acetonide in a durable intravitreal implant across a variety of patients with chronic non-infectious uveitis affecting the posterior segment. The initial readout from the study is expected in the second half of next year and could potentially benefit both YUTIQ in the United States and ILUVIEN in Europe and the Middle East.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the appointment of Elliot Maltz, C.P.A., as Chief Financial Officer. Mr. Maltz brings extensive experience from public international commercial-stage companies and will play a key role in enhancing the company's growth trajectory and driving improved cash flow. The company also approved an inducement option to purchase up to 75,000 shares of common stock for Mr. Maltz.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the appointment of Todd Wood as President U.S. effective immediately. Mr. Wood brings extensive commercial leadership experience from the pharmaceutical and medical device industries, including leading the eye care sales organization at Allergan. The company also granted an inducement option to purchase up to 125,000 shares of common stock to Mr. Wood.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
management
-
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax brings extensive operational experience and a history of strong leadership in the life sciences industry, which will provide new and unique perspectives as Alimera continues to scale. Her appointment comes at an exciting stage of growth for Alimera, following the acquisition of YUTIQ in the U.S. and continued expansion in international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
management
-
Rhea-AI Summary
Alimera Sciences, Inc. announces that clinical data for ILUVIEN® will be featured in three posters and a presentation at the American Academy of Ophthalmology’s 127th Annual Meeting. The data comes from the PALADIN study, which evaluates the long-term safety of ILUVIEN for patients with diabetic macular edema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
Rhea-AI Summary
Alimera Sciences reports Q3 2023 financial results, with net revenue up 72% to $23.4 million and net loss decreased by 74% to $1.4 million. Adjusted EBITDA of $5.4 million. Successful integration of YUTIQ into the U.S. segment. Alimera expects over $100 million in net revenue and more than $20 million in Adjusted EBITDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.99%
Tags
-
Rhea-AI Summary
Alimera Sciences announces clinical data for ILUVIEN and YUTIQ will be featured in presentations at Retina Society's Annual Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
none
-
Rhea-AI Summary
Alimera Sciences appoints Jason Werner as COO and Dr. Philip Ashman as President of International Operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
management
Rhea-AI Summary
Alimera Sciences Inc. to present corporate overview at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
conferences

FAQ

What is the current stock price of Alimera Sciences (ALIM)?

The current stock price of Alimera Sciences (ALIM) is $5.54 as of February 7, 2025.

What is the market cap of Alimera Sciences (ALIM)?

The market cap of Alimera Sciences (ALIM) is approximately 301.3M.

What is the core focus of Alimera Sciences?

Alimera Sciences specializes in research, development, and commercialization of prescription ophthalmic pharmaceuticals, with a primary focus on treating retinal diseases.

How does Alimera address unmet needs in ophthalmology?

By employing advanced sustained release technologies like CONTINUOUS MICRODOSING™, Alimera’s products are designed to deliver continuous, low-dose medication to manage retinal conditions effectively.

What are the main products in Alimera’s portfolio?

The company’s portfolio includes products designed to treat conditions such as diabetic macular edema and non-infectious uveitis, utilizing sustained release implants to reduce treatment frequency.

How does Alimera generate revenue?

Revenue is primarily generated through the prescription sales of its ophthalmic implants and other related products, targeting both domestic and international markets.

In which markets does Alimera Sciences operate?

Alimera operates globally, with significant market presence in the United States and across several European countries through its subsidiary based in London.

What distinguishes Alimera’s technology from other treatments?

Its use of sustained release technology allows for continuous, controlled dosing, reducing the need for frequent injections and potentially maintaining vision for longer periods compared to conventional therapies.

How does Alimera contribute to clinical research?

The company actively engages in clinical trials and collaborates with established research networks, ensuring that its products meet rigorous efficacy and safety standards while addressing complex retinal conditions.

Who are the primary beneficiaries of Alimera’s treatments?

Patients suffering from retinal diseases, along with retina specialists looking for advanced solutions to manage ocular conditions, benefit from Alimera’s targeted pharmaceutical innovations.
Alimera Sciences

Nasdaq:ALIM

ALIM Rankings

ALIM Stock Data

301.29M
51.48M
5.35%
86.54%
1.06%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ALPHARETTA